First Mercantile Trust Co Lowers stake in Hologic (HOLX)

Hologic (HOLX) : First Mercantile Trust Co reduced its stake in Hologic by 20.66% during the most recent quarter end. The investment management company now holds a total of 21,500 shares of Hologic which is valued at $854,410 after selling 5,600 shares in Hologic , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Hologic makes up approximately 0.11% of First Mercantile Trust Co’s portfolio.

Other Hedge Funds, Including , Simplex Trading reduced its stake in HOLX by selling 3,125 shares or 25.02% in the most recent quarter. The Hedge Fund company now holds 9,365 shares of HOLX which is valued at $372,165. Hologic makes up approx 0.05% of Simplex Trading’s portfolio.Chevy Chase Trust Holdings boosted its stake in HOLX in the latest quarter, The investment management firm added 23,788 additional shares and now holds a total of 231,500 shares of Hologic which is valued at $9,151,195. Hologic makes up approx 0.05% of Chevy Chase Trust Holdings’s portfolio.Curbstone Financial Management Corp reduced its stake in HOLX by selling 350 shares or 2.63% in the most recent quarter. The Hedge Fund company now holds 12,956 shares of HOLX which is valued at $512,151. Hologic makes up approx 0.17% of Curbstone Financial Management Corp’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in HOLX by selling 8,446 shares or 52.07% in the most recent quarter. The Hedge Fund company now holds 7,774 shares of HOLX which is valued at $307,306.Washington Trust Bank reduced its stake in HOLX by selling 368 shares or 92.93% in the most recent quarter. The Hedge Fund company now holds 28 shares of HOLX which is valued at $1,107.

Hologic opened for trading at $39.39 and hit $39.9101 on the upside on Friday, eventually ending the session at $39.74, with a gain of 1.20% or 0.47 points. The heightened volatility saw the trading volume jump to 29,82,062 shares. Company has a market cap of $11,025 M.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.